← Leaderboards
Andreas H Kottmann
Psychogenics, Inc.
$1,508,365
Attributed
$1,508,365
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $329.8K · FY2007–21$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,508,365 · 4
By mechanism
R21$1,384,459 · 3
R43$123,906 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Parkinson Disease”
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$92,426,001
- David M Anderson · University Of Washington$40,483,703
- Daniel M Corcos · Northwestern University$37,632,589
- Joel Synes Perlmutter · Washington University$37,192,743
- Jerrold L Vitek · University Of Minnesota$35,135,315
- Joseph B Martin · Harvard University (Medical School)$26,652,023
Research focus
Parkinson DiseaseCholinergicDopaminergic NeuronTissuesCorpus Striatum StructureNeuronsBrainGeneticAlzheimer&AposBasal GangliaDoseAllelesSignal TransductionAffinity ChromatographyNerve DegenerationPharmaceutical PreparationsAnimalsAdultAblationMouse ModelG-Protein-Coupled ReceptorsInterneuronsAgonistShh Gene
Grant awards (8)
Mechanisms of Inhibition of L-Dopa Induced Dyskinesia (LID) by GPCR Smoothened Activation.$196,250
R21 · FY2021 · AG · contact PI
Identification of protein targets of Smo signaling in cholinergic neurons that degenerate in Alzheimerâs Disease.$133,552
R21 · FY2021 · AG · contact PI
Mechanisms of Inhibition of L-Dopa Induced Dyskinesia (LID) by GPCR Smoothened Activation.$235,500
R21 · FY2020 · AG · contact PI
Activation of the GPCR Smoothened as a treatment of L-Dopa Induced dyskinesia$196,250
R21 · FY2017 · NS · contact PI
Activation of the GPCR Smoothened as a treatment of L-Dopa Induced dyskinesia$235,500
R21 · FY2016 · NS · contact PI
Maintenance and Neuroprotection$176,094
R21 · FY2008 · NS · contact PI
Maintenance and Neuroprotection$211,313
R21 · FY2007 · NS · contact PI
Development of Amygdala specific monoclonal Antibodies$123,906
R43 · FY2002 · MH